Publicacións en colaboración con investigadores/as de University Medical Center Hamburg-Eppendorf (25)

2024

  1. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

    eClinicalMedicine, Vol. 71

2023

  1. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

    Haematologica

  2. Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry

    International Journal of Antimicrobial Agents, Vol. 62, Núm. 4

  3. Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry

    Journal of hematology & oncology

  4. von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS

    Journal of Thrombosis and Haemostasis, Vol. 21, Núm. 4, pp. 787-799

2022

  1. Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS study

    Journal of Thrombosis and Haemostasis, Vol. 20, Núm. 5, pp. 1106-1114

2020

  1. Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS-IPS, an international and collaborative cross-sectional study

    Journal of Thrombosis and Haemostasis, Vol. 18, Núm. 9, pp. 2145-2154

2019

  1. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

    The Lancet Oncology, Vol. 20, Núm. 6, pp. 781-794

2015

  1. Identification and characterization of novel variations in platelet G-protein coupled receptor (GPCR) genes in patients historically diagnosed with type 1 von Willebrand disease

    PLoS ONE, Vol. 10, Núm. 12

2013

  1. VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease

    Blood, Vol. 121, Núm. 12, pp. 2336-2339

2011

  1. A comparison between two semi-quantitative bleeding scales for the diagnosis and assessment of bleeding severity in type 1 von Willebrand disease

    Haemophilia

2010

  1. ITER study of patients with haemo philia A and factor VIII inhibitors

    Hamostaseologie, Vol. 30, Núm. SUPPL.1, pp. 46-47

  2. Sequential combined bypassing therapy of bleeds unresponsive to a single bypassing agent Safety and efficacy: Safety and efficacy

    Hamostaseologie, Vol. 30, Núm. SUPPL.1, pp. 54-55

  3. The impact of bleeding history, von willebrand factor and PFA-100® on the diagnosis of type 1 von willebrand disease: Results from the european study MCMDM-1VWD

    British Journal of Haematology, Vol. 151, Núm. 3, pp. 245-251

  4. Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD

    Thrombosis Research, Vol. 126, Núm. 3, pp. 227-231

2009

  1. Expression of 14 von Willebrand factor mutations identified in patients with type.1 von Willebrand disease from the MCMDM-1VWD study

    Journal of Thrombosis and Haemostasis, Vol. 7, Núm. 8, pp. 1304-1312

2008

  1. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD)

    Journal of Thrombosis and Haemostasis, Vol. 6, Núm. 5, pp. 762-771

  2. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the european study: Molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD)

    Blood, Vol. 111, Núm. 10, pp. 4979-4985

  3. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): Results from the European Study MCMDM-1VWD

    Blood, Vol. 111, Núm. 7, pp. 3531-3539

2007

  1. Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: Results from a multicenter European study (MCMDM-1VWD)

    Journal of Thrombosis and Haemostasis, Vol. 5, Núm. 4, pp. 715-721